Poolbeg Pharma PLC pushes further with vaccine

Poolbeg Pharma PLC’s chief executive Jeremy Skillington talked to Proactive about the completion of in-licensing of a new vaccine candidate, POLB 003.

This new vaccine-in-waiting could prove decisive in the battle against melioidosis – also known as Whitmore’s disease – an infectious bacterial condition that in some cases can prove fatal.

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews